Sarepta Therapeutics Inc SRPT.O:
SAREPTA ANNOUNCES FIRST CLINICAL DATA FROM SIRNA PIPELINE TARGETING FSHD1 AND DM1
SAREPTA THERAPEUTICS INC - SIRNA ACHIEVES HIGH MUSCLE CONCENTRATIONS WITHOUT DOSE LIMITING TOXICITY FOR FSHD1 AND DM1
SAREPTA THERAPEUTICS INC - PROOF-OF-CONCEPT DATA SHOW SINGLE DOSE OF SRP-1001 AND SRP-1003 REDUCES TARGET PROTEIN OR MRNA
SAREPTA THERAPEUTICS INC - MAJORITY OF ADVERSE EVENTS IN STUDIES WERE MILD TO MODERATE AND NOT DOSE DEPENDENT